Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06805825 · ClinicalTrials.gov registry record · Phase 1
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
A Phase 1 study of Small-cell Lung Cancer and Neuroendocrine Tumors, sponsored by Novelty Nobility.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 67
- Enrollment target
- 5
- Study locations
NCT06805825: Recruiting Phase 1 study of Small-cell Lung Cancer and Neuroendocrine Tumors, sponsored by Novelty Nobility.
NCT06805825 is a Phase 1 study of Small-cell Lung Cancer and Neuroendocrine Tumors that is actively recruiting participants, run by Novelty Nobility. The registered enrollment target is 67 participants, below the 231-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (71% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06805825, a Phase 1 study of Small-cell Lung Cancer and Neuroendocrine Tumors, is actively recruiting participants, sponsored by Novelty Nobility.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 67 participants
- Enrollment target
- 5
- Study locations
Study Summary
This open-label clinical trial will evaluate the safety and tolerability of NN3201 in subjects with advanced and/or metastatic solid tumors known to express c-Kit.
Primary Outcome
A DLT is defined as an AE that meets at least one of the criteria listed in protocol, according to National Cancer Institute (NCI) common terminology criteria for AE (CTCAE) version 5.0 and is considered by the investigator to be clinically relevant and attributed to the study treatment during the first 21 days after the first dose of study treatment.
Conditions Studied
Interventions
- DRUG NN3201
Study Locations (5)
Michigan
- University of Michigan Hospitals - Ann Arbor
Ohio
- Case Comprehensive Cancer Center - Cleveland
Oregon
- Oregon Health & Science University - Portland
Texas
- The University of Texas MD Anderson Cancer Center - Houston
Virginia
- NEXT Virginia - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2025-02-03 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 1 |
What NCT06805825 shows while recruiting
NCT06805825 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 67 participants, a relatively small participant target, below the 231-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (71% lower).
The record links to 7 conditions, with Small-cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which NN3201 is the first listed.
NCT06805825 lists 5 locations in 5 states (Michigan, Ohio, Oregon).
Frequently Asked Questions
What is clinical trial NCT06805825 about?
NCT06805825 is a clinical study titled "A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit". This open-label clinical trial will evaluate the safety and tolerability of NN3201 in subjects with advanced and/or metastatic solid tumors known to express c-Kit.
What is the current status of trial NCT06805825?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 67 participants. The study started on 2025-02-03. Estimated completion is 2027-12-31.
What conditions does trial NCT06805825 study?
This clinical trial studies the following conditions: Small-cell Lung Cancer, Neuroendocrine Tumors, Clear Cell Renal Cell Carcinoma, Uveal Melanoma, Adenoid Cystic Carcinoma.
What interventions are being tested in trial NCT06805825?
The interventions under investigation include: NN3201 (DRUG).
Who is sponsoring clinical trial NCT06805825?
This trial is sponsored by Novelty Nobility, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06805825 being conducted?
This trial has 5 study locations across Michigan, Ohio, Oregon, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Small-cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06805825's enrollment target sits among peer trials
67 46th of 79 higher than 34 of 79 other Small-cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Small-cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of MGC026 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial)
RECRUITING · Phase 1
-
Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
RECRUITING · Phase 1
-
A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03213002 · 67 participants · Phase 1
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
- NCT04115163 · 67 participants · Phase 2
Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
- NCT04315324 · 67 participants · Phase 1
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
- NCT04532424 · 67 participants · NA
Transcranial Magnetic Stimulation for Restricted and Repetitive Behavior in ASD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI